Table 1.
Demographics and clinical characteristics of patients included in the study
| Variable | Value |
|---|---|
| Total population | 29 patients |
| Median age, years (± IQR) | 37.0 ± 37.0 |
| Age group, n (%) | |
| < 18 years | 7 (24.1) |
| ≥ 18 years | 22 (75.9) |
| Sex, male, n (%) | 20 (69.0) |
| Age at onset of atopic dermatitis, n (%) | |
| Child | 22 (75.9) |
| Teenager | 1 (3.4) |
| Adult | 6 (20.7) |
| History of personal atopy, n (%) | |
| Allergic asthma | 8 (53.3) |
| Allergic rhino-conjunctivitis | 8 (53.3) |
| Missing, n/n total | 14/29 (48.3) |
| Previous topical treatments for atopic dermatitis, n (%) | |
| Emollients | 23 (100.0) |
| Topical corticosteroids | 23 (100.0) |
| Topical immunomodulators | 12 (52.2) |
| Missing, n/n total | 6/29 (20.7) |
| Previous systemic treatments for atopic dermatitis, n (%) | |
| Oral corticosteroids | 11 (37.9) |
| Cyclosporine | 18 (62.0) |
| Acitretin | 1 (3.4) |
| Phototherapy | 2 (6.9) |
| Methotrexate | 4 (13.8) |
| Dupilumab | 10 (34.5) |
| Failure of treatment, n/n total | 9/10 |
| Adverse events, n/n total | 1/10 |
| Tralokinumab | 3 (10.3) |
| Failure of treatment, n/n total | 3/3 |
| Nemolizumab | 2 (6.9) |
| Failure of treatment, n/n total | 2/2 |
| Baricitinib | 7 (24.1) |
| Failure of treatment, n/n total | 7/7 |
| Clinical severity at baseline, median (± IQR) | |
| v-IGA-AD | |
| Adults | 4 ± 1 |
| Adolescents | 4 ± 0 |
| EASI | |
| Adults | 22.0 ± 4.6 |
| Adolescents | 23.4 ± 3.8 |
v-IGA-AD validated Investigator’s Global Assessment for atopic dermatitis, EASI Eczema Area and Severity Index, IQR interquartile range